Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches

Migraine Clinical Trial

Official title:

A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00210821
• Other study ID #: CR004666
• Status: Completed
• Phase: Phase 3
• First received: September 13, 2005
• Last updated: June 8, 2011
• Start date: February 2004
• Est. completion date: November 2005

Study information

• Verified date: May 2010
• Source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness and safety of two treatment regimens in preventing migraines. The antidepressant amitriptyline has been used successfully to prevent migraine headaches.

Description:

People who suffer from migraines have many prescription medications to choose from, both to treat the migraine and to prevent it from starting. However, many patients have not had success in finding the drug that helps them best. Amitriptyline, an antidepressant, has been used successfully for many years to prevent migraine headaches. This study will compare the effectiveness of amitriptyline with the effectiveness of topiramate, an anti-seizure drug, in preventing migraines. The safety of both drugs will also be assessed. The objective of the study is to demonstrate that topiramate will be at least as effective as amitriptyline in preventing migraines. During the first 4 weeks of the study, topiramate or amitriptyline will be increased by 25 mg per week up to a total dose of 100 mg per day or up to the maximum tolerated dose, whichever is less. Treatment will continue at 100 mg per day for 22 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 347
• Est. completion date: November 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Migraine headache for at least 6 months, with 3 to 12 headaches a month for the previous 3 months

• no more than 15 headache days in the previous month before study start

• no heart rhythm problems or neurologic problems

• women must not be pregnant and must use birth control

Exclusion Criteria:

• Cannot have failed at least 2 previous trials of migraine prevention drugs

• cannot have failed a previous trial of topiramate or amitriptyline

• no cluster headaches

• no migraine with aura without headache

• no pain that is worse than the migraine pain

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Headache
• Migraine
• Migraine Disorders

Intervention

Drug:
• topiramate

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Ortho-McNeil Neurologics, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in the average monthly migraine episode rate.
Secondary	Change in average monthly rate of days with migraine headache; change in average monthly rate of headache (migraine & non-migraine) days; change in average monthly rate of acute abortive medications; weight changes; quality of life assessments

External Links

•   Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis